We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Addresses a Major Diabetes Care Gap With Tech Innovation
Read MoreHide Full Article
Key Takeaways
Abbott secured CE Mark for Libre Duo and Libre Duo 10 Day dual glucose-ketone sensors.
ABT's systems track glucose and ketones every minute and alert users to rising ketone levels.
Abbott plans Libre ecosystem integration and expanded MiniMed sensor commercialization.
Illinois-based Abbott (ABT - Free Report) extended its solid track record in health-tech innovation by securing the CE Mark for the first-ever dual glucose-ketone sensing technology for people with diabetes. The systems, named Libre Duo and Libre Duo 10 Day, are designed to measure glucose and ketone levels every minute, giving real-time visibility into glucose levels needed for daily diabetes management.
The devices also alert users when ketone levels continue to rise, leading to a diabetic ketoacidosis (DKA) emergency. The phenomenon occurs when the body does not have enough insulin and begins breaking down fat for energy. Abbott says the systems also reduce reliance on traditional blood or urine tests that capture only a single moment in time.
DKA remains a growing gap in diabetes care since ketones are not routinely monitored, allowing warning signs to go unnoticed and increasing the risk of delayed intervention. Several recent studies, including research published in the peer-reviewed journal Diabetes Care, illustrate the extent of these challenges.
Libre Duo delivers up to 15 days of wear and will be offered to adults aged 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people aged two and older. The systems align with recommendations from a recent international expert consensus paper from Breakthrough T1D. Abbott plans to integrate the systems with its Libre digital health ecosystem, enabling users to share glucose and ketone data with caregivers and healthcare providers.
The company is also working with major pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. Recently, Medtronic’s Diabetes operating unit, MiniMed (MMED - Free Report) , has expanded its agreement with Abbott to commercialize these dual glucose-ketone sensors. The agreement builds on the companies' existing partnership around Abbott’s Instinct sensor and will offer MiniMed users a broader choice across its AID and Smart Multiple Daily Injections systems.
What Is ABT’s Major Diabetes Rival Up To?
At the Investor Day 2026, Dexcom’s (DXCM - Free Report) CEO has outlined three drivers that are going to define the next phase of its journey: an advanced product portfolio, expanding global access for people to CGM at a rate faster than penetration and durable double-digit growth combined with strong cash flow generation.
The company also introduced its next-generation G8 platform, nearly 50% smaller than the G7 sensor, with advanced sensing capabilities and enhanced accuracy, connectivity and system design. Dexcom teams are gearing toward submission of this product next year to facilitate a launch either at the end of 2027 or early 2028.
The Zacks Rundown for ABT Stock
Over the past 12 months, Abbott shares have plunged 35.1%, wider than the industry’s 32.4% decline.
Image Source: Zacks Investment Research
In terms of valuation, ABT trades at a forward, five-year Price/Sales (P/S) of 2.89X, lower than its 4.64X median but higher than the industry average of 1.99X.
Image Source: Zacks Investment Research
Take a look at how estimates for Abbott’s FY 2026 and 2027 earnings are shaping up.
View the Zacks #1 Rank List
Image: Bigstock
Abbott Addresses a Major Diabetes Care Gap With Tech Innovation
Key Takeaways
Illinois-based Abbott (ABT - Free Report) extended its solid track record in health-tech innovation by securing the CE Mark for the first-ever dual glucose-ketone sensing technology for people with diabetes. The systems, named Libre Duo and Libre Duo 10 Day, are designed to measure glucose and ketone levels every minute, giving real-time visibility into glucose levels needed for daily diabetes management.
The devices also alert users when ketone levels continue to rise, leading to a diabetic ketoacidosis (DKA) emergency. The phenomenon occurs when the body does not have enough insulin and begins breaking down fat for energy. Abbott says the systems also reduce reliance on traditional blood or urine tests that capture only a single moment in time.
DKA remains a growing gap in diabetes care since ketones are not routinely monitored, allowing warning signs to go unnoticed and increasing the risk of delayed intervention. Several recent studies, including research published in the peer-reviewed journal Diabetes Care, illustrate the extent of these challenges.
Libre Duo delivers up to 15 days of wear and will be offered to adults aged 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people aged two and older. The systems align with recommendations from a recent international expert consensus paper from Breakthrough T1D. Abbott plans to integrate the systems with its Libre digital health ecosystem, enabling users to share glucose and ketone data with caregivers and healthcare providers.
The company is also working with major pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. Recently, Medtronic’s Diabetes operating unit, MiniMed (MMED - Free Report) , has expanded its agreement with Abbott to commercialize these dual glucose-ketone sensors. The agreement builds on the companies' existing partnership around Abbott’s Instinct sensor and will offer MiniMed users a broader choice across its AID and Smart Multiple Daily Injections systems.
What Is ABT’s Major Diabetes Rival Up To?
At the Investor Day 2026, Dexcom’s (DXCM - Free Report) CEO has outlined three drivers that are going to define the next phase of its journey: an advanced product portfolio, expanding global access for people to CGM at a rate faster than penetration and durable double-digit growth combined with strong cash flow generation.
The company also introduced its next-generation G8 platform, nearly 50% smaller than the G7 sensor, with advanced sensing capabilities and enhanced accuracy, connectivity and system design. Dexcom teams are gearing toward submission of this product next year to facilitate a launch either at the end of 2027 or early 2028.
The Zacks Rundown for ABT Stock
Over the past 12 months, Abbott shares have plunged 35.1%, wider than the industry’s 32.4% decline.
Image Source: Zacks Investment Research
In terms of valuation, ABT trades at a forward, five-year Price/Sales (P/S) of 2.89X, lower than its 4.64X median but higher than the industry average of 1.99X.
Image Source: Zacks Investment Research
Take a look at how estimates for Abbott’s FY 2026 and 2027 earnings are shaping up.
Image Source: Zacks Investment Research
Abbott currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.